Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]
Verona Pharma Announces December 2024 Investor Conference Participation
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]